bullish
[RemeGen (9995 HK) Target Price Change]: Chinese Biotech Must Confine to the Biotech Role
405 Views05 May 2023 17:17
RemeGen’s C1Q23 top line came in as 31% of our C1H23 estimate while IFRS operating loss came in as 55%. C1Q23 gross margin exceeded our C1H23 estimate by 12ppt, mainly due to restraining in shipment;
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 2-minute read)
Discussions
(Paid Plans Only)
Top Quartile
Blue Lotus Research Institute
China growth and global non-US Internet equities
- [RemeGen (9995 HK) Target Price Change]: Chinese Biotech Must Confine to the Biotech Role05 May 2023
- [RemeGen (9995 HK) Target Price Change]: Provision for License Out Absence Is Adequate31 Mar 2023
x